Erythropoietin (EPO) vs LL-37
Updated August 25, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Erythropoietin (EPO) and LL-37 (also searched as LL-37 vs Erythropoietin (EPO)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Erythropoietin (EPO) centers on healing, while LL-37 leans toward healing. On indexed research, Erythropoietin (EPO) is ahead (Erythropoietin (EPO): 27 studies, Human evidence; LL-37: 24, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Erythropoietin (EPO) is strongest for healing; LL-37 for healing.
- •Evidence: Erythropoietin (EPO) Human evidence (27 studies) vs LL-37 Human evidence (24).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Erythropoiesis | Anemia treatment
Antimicrobial | Wound healing
Erythropoietin (EPO) vs LL-37: side-by-side
| Metric | Erythropoietin (EPO) | LL-37 |
|---|---|---|
| Class | Healing | Immune |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 27 | 24 |
| Research level | Extensively Studied | Moderate Research |
| Strongest effect | Healing & recovery | Healing & recovery |
| Healing & recovery | 4.0▲ | 4.0▲ |
| Muscle & body comp | 0.0 | 1.0▲ |
| Metabolic & appetite | 3.0▲ | 2.0 |
| Neuro & mood | 0.0 | 1.0▲ |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 0.0 | 4.0▲ |
| Skin & aesthetics | 0.0 | 2.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Erythropoietin (EPO) | LL-37 |
|---|---|---|
| Mechanism | EpoR agonist | Disruption of microbial membranes and modulation of immune responses |
| Route | Subcutaneous injection | — |
| Half-life | ~4–13 hours | — |
| Time to peak | ~12–24 hours | — |
| Duration of action | ~1 week | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Erythropoietin (EPO)?
Erythropoietin (EPO) is a glycoprotein hormone that stimulates red blood cell production in bone marrow, used clinically for anemia and studied in hematology and metabolic research.
Full Erythropoietin (EPO) profile, mechanism & studies →What is LL-37?
LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in the innate immune response, exhibiting antimicrobial, immunomodulatory, and wound healing properties. Its diverse functions make it a subject of interest in various fields of biomedical research.
Full LL-37 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Even | Both ~4.0/5 |
| Muscle | LL-37 | 1.0/5 effect signal |
| Metabolic | Erythropoietin (EPO) | 3.0/5 effect signal |
| Neuro | LL-37 | 1.0/5 effect signal |
| Inflammation | LL-37 | 4.0/5 effect signal |
| Skin | LL-37 | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Erythropoietin (EPO) and LL-37?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Erythropoietin (EPO) vs LL-37: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Erythropoietin (EPO) has 27 approved studies indexed (Human evidence), and LL-37 has 24 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Erythropoietin (EPO) or LL-37 better?
It depends on your goal. Erythropoietin (EPO) is strongest for healing; LL-37 for healing. Erythropoietin (EPO) has more indexed studies (27). See the goal-by-goal breakdown above.
Is Erythropoietin (EPO) or LL-37 better for weight loss?
Erythropoietin (EPO) shows the stronger metabolic & appetite profile (3.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Erythropoietin (EPO) or LL-37 better for muscle?
LL-37 leads on the muscle & body-composition axis (1.0/5).
Which has more research, Erythropoietin (EPO) or LL-37?
Erythropoietin (EPO) has 27 approved studies indexed (Human evidence); LL-37 has 24 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Erythropoietin (EPO) and LL-37?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Erythropoietin (EPO) vs LL-37?
Erythropoietin (EPO): no community-reported effects logged yet. LL-37: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Erythropoietin (EPO) or LL-37 FDA-approved?
Erythropoietin (EPO) is a research-use compound and is not FDA-approved. LL-37 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is LL-37 better than Erythropoietin (EPO)?
For healing, LL-37 has the edge; for healing, Erythropoietin (EPO) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Erythropoietin (EPO) and LL-37 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed August 25, 2026.